Tag Archives: anti-PD-1

October, 2018

August, 2018

July, 2018

April, 2018

October, 2017

September, 2017

July, 2017

  • 21 July

    COX-2 Inhibitors May Reverse IDO1-Mediated Immunosuppression in Some Cancers

    Bottom Line: In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to anti-PD1 therapies. Journal in Which the Study was Published: Cancer Immunology Research, …

  • 6 July

    Celgene Enters Cancer Immunotherapy Deal with BeiGene for its Investigational PD-1 Inhibitor

    SUMMIT, N.J. & BEIJING–(BUSINESS WIRE)– Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers in the United States, Europe, Japan and rest of world outside Asia. BeiGene will retain exclusive rights for the development and commercialization of BGB-A317 for hematological malignancies globally …

May, 2017